New development of lipid-lowering therapy of coronary heart disease: Inclisiran / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
; (12): 365-368, 2022.
Article
en Zh
| WPRIM
| ID: wpr-1014854
Biblioteca responsable:
WPRO
ABSTRACT
Because of high rate of nonadherence to statins, the subcutaneously injection of Inclisiran therapy intervals are from 3 months to 6 months, which will increase the patients' adherence to the Inclisiran therapy. In this review, we summarize the latest advances of Inclisiran, and review the phase 2 and phase 3 clinical trials results, adverse events, and the clinical trials results in progress of Inclisiran. Finally, we discuss the current status of Inclisiran in the clinical works.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Clinical Pharmacology and Therapeutics
Año:
2022
Tipo del documento:
Article